scholarly journals Risk of nevirapine-associated Stevens-Johnson syndrome among HIV-infected pregnant women: The Medunsa National Pharmacovigilance Centre, 2007 - 2012

2013 ◽  
Vol 103 (5) ◽  
pp. 322 ◽  
Author(s):  
Nomathemba Dube ◽  
E Adewusi ◽  
R Summers
Keyword(s):  
Pregnant Women ◽  
Stevens Johnson Syndrome ◽  
Pharmacovigilance Centre ◽  
National Pharmacovigilance Centre ◽  
Johnson Syndrome

scholarly journals Stevens Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Nevirapine among HIV-Infected Pregnant Women: Five Cases

2017 ◽  
Vol 08 (08) ◽  
Author(s):  
Boubacar Ahy Diatta ◽  
Omar Gassama ◽  
Saer Diadie ◽  
Moussa Diallo ◽  
Suzanne Oumou Niang ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Toxic Epidermal Necrolysis ◽  
Stevens Johnson Syndrome ◽  
Johnson Syndrome

Stevens-Johnson syndrome from ophthalmic sulfonamide

1976 ◽  
Vol 112 (4) ◽  
pp. 513-514 ◽  
Author(s):  
H. R. Gottschalk
Keyword(s):  
Stevens Johnson Syndrome ◽  
Johnson Syndrome

Stevens-Johnson Syndrome, fisiopatológics aspects: A literature review

2016 ◽  
Vol 06 (08) ◽  
pp. 40-51
Author(s):  
Alex Ferreira de Oliveira ◽  
Ingrith do Socorro Neves da Silva ◽  
Lídia Pinheiro de Brito ◽  
Rebeca Luiza Abreu Pereira ◽  
Amanda Alves Fecury ◽  
...  
Keyword(s):  
Literature Review ◽  
Stevens Johnson Syndrome ◽  
Johnson Syndrome

Ciprofloxacin-induced Stevens-Johnson syndrome: First report from Bangladesh

2010 ◽  
Vol 4 (1) ◽  
pp. 199-202
Author(s):  
Mamun-Al-Mahtab ◽  
Salimur Rahman ◽  
Akmat Ali ◽  
Ananta Shrestha ◽  
Jahangir Sarkar ◽  
...  
Keyword(s):  
Stevens Johnson Syndrome ◽  
First Report ◽  
Johnson Syndrome

Pulmonary Thromboembolism Induced by Intravenous Immunoglobulin Therapy for Stevens-Johnson Syndrome : A Case Report

2019 ◽  
Vol 81 (3) ◽  
pp. 170-174 ◽  
Author(s):  
Taketoshi IDE ◽  
Maiko OHNO ◽  
Takamichi ITO ◽  
Karin TSUKAMOTO ◽  
Anna HIRANO ◽  
...  
Keyword(s):  
Case Report ◽  
Intravenous Immunoglobulin ◽  
Pulmonary Thromboembolism ◽  
Immunoglobulin Therapy ◽  
Stevens Johnson Syndrome ◽  
Intravenous Immunoglobulin Therapy ◽  
Johnson Syndrome

An update on HLA alleles as pharmacogenetic markers for antiepileptic drug-induced cutaneous adverse reaction

2019 ◽  
Vol 2 (2) ◽  
pp. 1-17
Author(s):  
Sue-Mian Then ◽  
Azman Ali Raymond
Keyword(s):  
Single Gene ◽  
Hypersensitivity Syndrome ◽  
Allelic Frequency ◽  
Stevens Johnson Syndrome ◽  
Case Control Studies ◽  
Drug Induced ◽  
Hla Alleles ◽  
Exfoliative Dermatitis ◽  
Johnson Syndrome ◽  
Systemic Symptoms

Epilepsy is a common neurological disorder affecting approximately 50 million people worldwide. Antiepileptic drugs (AEDs) are commonly used to treat the disease depending, mainly on the type of seizure. However, the use of AEDs may also lead to cutaneous adverse drug reactions (cADR) such as toxic epidermal necrolysis (TEN), Stevens–Johnson syndrome (SJS), exfoliative dermatitis (ED) and drug‐induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS), which are unwanted comorbidities in epilepsy. It was first discovered that the HLA-B*15:02 allele was strongly associated with carbamazepine (CBZ)-induced SJS/TEN among Han Chinese and this led to the discovery of other HLA alleles and cytochrome P450 (CYP) genes that were significantly associated with various AED-induced cADRs across various populations.  This mini review is an update on the latest findings of the involvement of various HLA alleles and CYP alleles in cADRs caused by CBZ, phenytoin (PHT), oxcarbazepine (OXC) and lamitrogine (LTG) in different case-control studies around the world. From our review, we found that CBZ- and PHT-induced cADRs were more commonly reported than the other AEDs. Therefore, there were more robust pharmacogenetics studies related to these AEDs. OXC- and LTG-induced cADRs were less commonly reported, and so more studies are needed to validate the reported association of the newer reported HLA alleles with these AEDs. It is also important to take into account the allelic frequency within a given population before drawing conclusions about the use of these alleles as genetic markers to prevent AED-induced cADR. Overall, the current body of research point to a combination of alleles as a better pharmacogenetic marker compared to the use of a single gene as a genetic marker for AED-induced cADR.

Sign in / Sign up

Export Citation Format

Share Document